PMID: 16614619Apr 15, 2006Paper

New therapeutic approaches to autoimmune diseases

La Presse médicale
Zahir Amoura, Jean-Charles Piette

Abstract

Over the past decade, new biological therapies have been developed to treat systemic autoimmune diseases. These new treatments, which target various steps of the immune response, include: B lymphocyte (BL) inhibitors, such as anti-CD20 monoclonal antibodies, BlyS antagonists, and tolerogens that inhibit specific BLs that produce pathogenic antibodies; inhibitors of costimulation between antigen-presenting cells and T lymphocytes (TL), such as monoclonal antibodies against CD40 ligand and CTLA4-Ig (abatecept); TL antagonists, which can inhibit proliferation of autoreactive T cells; cytokine antagonists; chemokine and adhesin antagonists, which inhibit trafficking of immunocompetent cells to target organs. These new approaches are based on a deeper understanding of the autoimmune response.

Citations

Aug 21, 2021·Immunopharmacology and Immunotoxicology·Hakan Parlakpinar, Mehmet Gunata

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

Revue neurologique
Zahir Amoura, J-C Piette
La Revue de médecine interne
Zahir AmouraJ-C Piette
Revista médica de Chile
Ernesto CairoliRicard Cervera
Expert Opinion on Therapeutic Targets
Rodney W Stuart, Michael K Racke
© 2022 Meta ULC. All rights reserved